🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — November 2025

SOUL trial preliminary data — November 2025

JenMemphis Thu, Dec 19, 2024 at 2:50 AM 51 replies 2,130 viewsPage 1 of 11
This thread is more than 14 months old. Information may be outdated. Consider searching for more recent discussions.
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Dec 19, 2024 at 4:15 AM#1

Anyone else dealing with soul trial preliminary data november 2025 from a cost perspective?

I have been paying $280/month and I am trying to get insurance to cover it.

Share what you are paying and what you are getting — transparency helps everyone.

36 23MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 33 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Dec 19, 2024 at 4:32 AM#2
JenMemphis said:
SOUL trial preliminary data November 2025

I respect JenMemphis perspective but I think this oversimplifies things a bit. Re: SOUL trial preliminary data — the effect size varies considerably by population.

I am not saying JenMemphis wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Last edited: Dec 19, 2024 at 8:32 AM
20 23PharmHunterJen, TomTeleRx, DoseLogDan and 17 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Dec 19, 2024 at 4:49 AM#3

+1 to JenMemphis. Especially the point about "SOUL trial preliminary data November 20..." — I have seen the same in my own experience with SOUL trial preliminary.

Last edited: Dec 19, 2024 at 8:49 AM
33 23Dr.EndoIndy, tom_AK, josh_phd_bmore and 30 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Dec 19, 2024 at 5:06 AM#4

As a healthcare provider, I want to add some clinical context to this discussion on SOUL trial preliminary data November.

Building on what JenMemphis said — the evidence base here is well-established. The key publications to reference are from the SURMOUNT program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
1 12Dr.SurgeonPGH
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Dec 19, 2024 at 5:23 AM#5
TirzTom said:
Especially the point about "SOUL trial preliminary data November 20

Gonna push back on this one. SOUL trial preliminary data is not that straightforward in my experience. I have been on this for 18 months and the reality is messier than the trials suggest.

Don't get me wrong — the medication works. But adherence is harder than people admit. We should be honest about that.

28 2pat_auckland, Dr.GastroMayo, JakeBK_lifts and 25 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register